Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Concept/Terms
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Antineoplastic Drug Resistance
- Drug Resistance, Antineoplastic
- Resistance, Antineoplastic Drug
- Resistance, Antineoplastic Agent
- Antineoplastic Agent Resistance
- Neoplasm Drug Resistance
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in Harvard Catalyst Profiles by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 4 | 5 |
1996 | 1 | 3 | 4 |
1997 | 1 | 2 | 3 |
1998 | 5 | 4 | 9 |
1999 | 0 | 9 | 9 |
2000 | 3 | 6 | 9 |
2001 | 2 | 15 | 17 |
2002 | 9 | 17 | 26 |
2003 | 15 | 19 | 34 |
2004 | 12 | 28 | 40 |
2005 | 14 | 35 | 49 |
2006 | 15 | 36 | 51 |
2007 | 25 | 46 | 71 |
2008 | 34 | 36 | 70 |
2009 | 32 | 52 | 84 |
2010 | 47 | 48 | 95 |
2011 | 47 | 47 | 94 |
2012 | 43 | 67 | 110 |
2013 | 57 | 69 | 126 |
2014 | 76 | 79 | 155 |
2015 | 105 | 69 | 174 |
2016 | 107 | 86 | 193 |
2017 | 87 | 105 | 192 |
2018 | 94 | 99 | 193 |
2019 | 86 | 101 | 187 |
2020 | 88 | 101 | 189 |
2021 | 70 | 77 | 147 |
2022 | 9 | 34 | 43 |
2023 | 7 | 42 | 49 |
2024 | 0 | 5 | 5 |
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms. Mol Cancer Ther. 2024 Mar 04; 23(3):368-380.
-
Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More? Clin Cancer Res. 2024 Feb 01; 30(3):471-473.
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481.
-
A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology. Mol Pharmacol. 2024 Jan 10; 105(2):97-103.
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb; 30(2):498-506.
-
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma. Blood Cancer J. 2023 12 11; 13(1):184.
-
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. J Clin Invest. 2023 11 15; 133(22).
-
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer. Sci Rep. 2023 11 13; 13(1):19729.
-
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. Leukemia. 2023 12; 37(12):2367-2382.
-
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC. J Thorac Oncol. 2024 Mar; 19(3):434-450.